
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JNK1 CRISPR Activation Plasmid (m) | sc-424053-ACT | 20 µg | $397.00 | |||
JNK1 CRISPR Activation Plasmid (m2) | sc-424053-ACT-2 | 20 µg | $397.00 |
Mapk8 encodes c-Jun N-terminal kinase 1 (JNK1), a stress-activated MAP kinase that integrates extracellular cues to regulate transcription, apoptosis, proliferation, and cytokine signaling. JNK1 phosphorylates JUN and other AP-1 components downstream of MAP3K/MKK4/7 cascades, shaping gene programs involved in inflammation and cellular adaptation to oxidative, genotoxic, and ER stress. In mouse models, JNK1 activity is widely used to study immune signaling, metabolic homeostasis, and neuronal stress responses, with pathway dysregulation linked to chronic inflammatory phenotypes and tissue remodeling. These functions make Mapk8 a central node for dissecting MAPK cross-talk with NF-κB, insulin signaling, and mitochondrial stress pathways.
JNK1 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Mapk8 expression without altering the underlying DNA sequence.
JNK1 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Mapk8 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Mapk8 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous JNK1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Mapk8 locus and enabling the study of JNK1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of JNK1 pathway restoration in tumor cells with silenced or reduced Mapk8 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.